Stock Research for IMMU


Featured Broker: Ally Invest

Get the due diligence for another stock.


IMMU Stock Chart & Research Data

The IMMU chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMU chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


IMMU Due diligence Resources & Stock Charts

The IMMU stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IMMU Detailed Price Forecast - CNN Money CNN View IMMU Detailed Summary - Google Finance
Yahoo View IMMU Detailed Summary - Yahoo! Finance Zacks View IMMU Stock Research & Analysis -

Stock Analysis

TradeIdeas View IMMU Trends & Analysis - Trade-Ideas Barrons View IMMU Major Holders - Barrons
NASDAQ View IMMU Call Transcripts - NASDAQ Seeking View IMMU Breaking News & Analysis - Seeking Alpha
Spotlight View IMMU Annual Report - OTC Report View IMMU OTC Short Report -
TradeKing View IMMU Fundamentals - TradeKing Charts View IMMU SEC Filings - Bar Chart
WSJ View Historical Prices for IMMU - The WSJ Morningstar View Performance/Total Return for IMMU - Morningstar
MarketWatch View the Analyst Estimates for IMMU - MarketWatch CNBC View the Earnings History for IMMU - CNBC
StockMarketWatch View the IMMU Earnings - StockMarketWatch MacroAxis View IMMU Buy or Sell Recommendations - MacroAxis
Bullish View the IMMU Bullish Patterns - American Bulls Short Pains View IMMU Short Pain Metrics -

Social Media Mentions

StockTwits View IMMU Stock Mentions - StockTwits PennyStocks View IMMU Stock Mentions - PennyStockTweets
Twitter View IMMU Stock Mentions - Twitter Invest Hub View IMMU Investment Forum News - Investor Hub
Yahoo View IMMU Stock Mentions - Yahoo! Message Board Seeking Alpha View IMMU Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for IMMU - Insider Cow View Insider Transactions for IMMU - Insider Cow
CNBC View IMMU Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IMMU - OTC Markets
Yahoo View Insider Transactions for IMMU - Yahoo! Finance NASDAQ View Institutional Holdings for IMMU - NASDAQ

Stock Charts

FinViz View IMMU Stock Insight & Charts - StockCharts View IMMU Investment Charts -
BarChart View IMMU Stock Overview & Charts - BarChart Trading View View IMMU User Generated Charts - Trading View

Latest Financial News for IMMU

FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
Posted on Wednesday July 18, 2018

Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease. The PDUFA target action date is January 18, 2019.

Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks
Posted on Wednesday July 11, 2018 observes the following stocks for today: Five Prime Therapeutics Inc. (NASDAQ: FPRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Immunomedics Inc. (NASDAQ: IMMU), and Incyte Corp. (NASDAQ: INCY). Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. rose 1.02%, ending Tuesday's trading session at $16.87.

How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)?
Posted on Wednesday June 27, 2018

Stocks with market capitalization between $2B and $10B, such as Immunomedics Inc (NASDAQ:IMMU) with a size of US$4.32b, do not attract as much attention from the investing community as doRead More...

[$$] Immunomedics Chairman Buys $19M More in Stock
Posted on Thursday June 21, 2018

Two weeks ago, B. Riley analyst Madhu Kumar gushed about Immunomedics, writing in a report that the biotech could have a “blockbuster cancer drug” in IMMU-132, an antibody-drug conjugate that had shown promise in disrupting “multiple solid cancers.” Kumar initiated coverage of the biotech on June 6 at Buy with a $53 price target. On Friday, Immunomedics (IMMU) Chairman Behzad Aghazadeh bought $18.5 million worth of the company’s stock through venBio Select Fund, a hedge fund where he serves as managing partner and portfolio manager. Aghazadeh bought 575,000 Immunomedics shares through the company’s public offering at $24 each, and went to the open market to buy another 200,000 shares for a better average per-share price of $23.39.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.